Source: International Congress 2017 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Bellocchia (TORINO, TO, Italy). Long term effect of Omalizumab on severe asthma. 3966

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab improves asthma in long term therapy Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care Year: 2012 Functional effects of long term ICS treatment in controlled asthma Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Long term follow-up of near-fatal asthma Source: Eur Respir J 2002; 20: Suppl. 38, 199s Year: 2002 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 The effect of inhaled corticosteroids on the hypothalamic-pituitary-adrenal-axis in short term and long term treatment Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Long term prognosis in near fatal asthma Source: Eur Respir J 2006; 28: Suppl. 50, 231s Year: 2006 Clinical benefits and safety of long term treatment with Montelukast in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Omalizumab in severe asthma: real life study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Effect of inhaled steroids on long term prognosis of lung function in adults with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 664s Year: 2004 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020